Get the Stockscreener App
29.17
18.63%
4.58
After Hours:
28.79
-0.38
-1.30%
Agios Pharmaceuticals Inc stock is traded at $29.17, with a volume of 6.31M.
It is up +18.63% in the last 24 hours and up +10.12% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$24.59
Open:
$28
24h Volume:
6.31M
Relative Volume:
4.55
Market Cap:
$1.70B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
2.5678
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
+14.62%
1M Performance:
+10.12%
6M Performance:
-12.72%
1Y Performance:
-14.68%
1-Day Range:
$27.10
$30.04
1-Week Range:
$24.16
$30.04
52-Week Range:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
29.17 | 1.43B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Agios (AGIO) Gets 18.6% Boost from Aqvesme OK - Finviz
Agios Pharmaceuticals price target raised to $34 from $32 at BofA - Yahoo Finance
Agios Stock (+19%): AQVESME Thalassemia Approval Ignites Re-Rate - Trefis
Agios Pharma shares jump as US FDA expands approval for blood disorder drug - Reuters
Truist Financial Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock - MarketBeat
Agios Pharma stock price target raised to $62 from $48 at H.C. Wainwright - Investing.com UK
Agios Pharma Stock: A Buy After FDA Approves Aqvesme (NASDAQ:AGIO) - Seeking Alpha
Here's Why Shares in Agios Pharmaceuticals Popped Today - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Here's Why Shares in Agios Pharmaceuticals Popped Today - The Motley Fool
First oral anemia treatment across thalassaemia types approved in USA - The Pharma Letter
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label - Yahoo Finance
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug - Yahoo Finance
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up on Analyst Upgrade - MarketBeat
The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy - FinancialContent
Agios Pharma shares jump 16% as US FDA expands approval for blood disorder drug - The Economic Times
Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat - TradingView — Track All Markets
Agios (AGIO) Surges 12% Following FDA Approval of New Thalassemi - GuruFocus
Agios Shares Rise After FDA Approves Aqvesme to Treat Anemia in Thalassemia Patients - marketscreener.com
Why Did AGIO Stock Surge 14% Today? - Stocktwits
Agios Pharmaceuticals stock soars after FDA approves AQVESME for thalassemia - Investing.com UK
Transcript : Agios Pharmaceuticals, Inc.Special Call - marketscreener.com
Bank of America Issues Positive Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price - MarketBeat
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug By Reuters - Investing.com
FDA Approves Agios Drug For Thalassemia-Associated Anemia - Benzinga
Agios Gets FDA Approval for Aqvesme to Treat Anemia in Thalassemia Patients - marketscreener.com
Assenagon Asset Management S.A. Purchases New Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals secures FDA approval for thalassemia treatment By Investing.com - Investing.com UK
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday - Benzinga
Agios Pharmaceuticals (AGIO) Secures FDA Approval for AQVESME - GuruFocus
AGIO: FDA approves AQVESME for anemia in thalassemia, showing strong efficacy and safety in Phase 3 trials - TradingView — Track All Markets
FDA approves Agios’ AQVESME for thalassemia anemia treatment By Investing.com - Investing.com Nigeria
FDA Approves Agios Pharmaceuticals' AQVESME (AGIO) for Thalassem - GuruFocus
New FDA-approved pill targets anemia in adults with alpha or beta thalassemia - Stock Titan
FDA approves Agios’ AQVESME for thalassemia anemia treatment - Investing.com
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia - The Manila Times
US FDA approves Agios' Aqvesme (mitapivat) for treatment of anemia in adults with alpha- or beta-thalassemia - marketscreener.com
Agios Pharmaceuticals Announces FDA Approval of AQVESME™ for Anemia Treatment in Thalassemia, the First FDA-Approved Medicine for Both Non-Transfusion-Dependent and Transfusion-Dependent Forms - Quiver Quantitative
How Agios Pharmaceuticals Inc. stock valuations compare to rivalsBullish Engulfing Patterns & High Profit Trading Alerts - Bollywood Helpline
Is Agios Pharmaceuticals Inc 8AP a good long term investmentDividend Aristocrats List & Fast Profit Investment Ideas - earlytimes.in
Alpha Thalassemia Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma - Barchart.com
Agios Pharmaceuticals (FRA:8AP) EV-to-OCF : -1.19 (As of Dec. 22, 2025) - GuruFocus
How Agios Pharmaceuticals Inc. stock reacts to Fed rate cutsAI-Driven Market Analysis & Free Tap Rapid Wealth - Bollywood Helpline
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Market Recap: How Agios Pharmaceuticals Inc stock responds to policy changesMarket Trend Review & Free Risk Controlled Daily Trade Plans - moha.gov.vn
Published on: 2025-12-21 02:46:20 - Bollywood Helpline
Is Agios Pharmaceuticals Inc. stock a safe haven assetWeekly Stock Recap & AI Driven Stock Movement Reports - Улправда
How strong is Agios Pharmaceuticals Inc. stock balance sheetJuly 2025 Big Picture & AI Powered Buy and Sell Recommendations - Улправда
Fundamentals Check: How Agios Pharmaceuticals Inc. stock reacts to Fed rate cuts - Улправда
Agios Pharmaceuticals, Inc. Being Investigated on Behalf of Agios Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Agios Pharmaceuticals (STU:8AP) EV-to-OCF : -1.22 (As of Dec. 19, 2025) - GuruFocus
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):